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Peroxisome proliferator-activated receptor g (PPARg), a member
of the nuclear hormone receptors, can act as ligand-sensitive tran-
scription factor (Mangelsdorf et al, 1995; Kliewer and Willson,
1998). Activated receptors heterodimerize with retinoid X
receptor (RXR) and can alter transcription of target genes after
binding to peroxisome proliferator responsive elements (PPRE)
(Kliewer et al, 1992). PPARg was initially reported for its regula-
tory roles in insulin sensitization and adipocyte differentiation
(Chawla et al, 1994; Tontonoz et al, 1994a, 1994b). However, later
studies have shown that PPARg is also expressed in other cell
types and it has recently been of interest for its role in cell prolifer-
ation and cancer. 
In vitro studies have revealed the growth inhibitory effects of
PPARg ligands on human cancer cells of different tissue origin,
including liposarcoma (Tontonoz et al, 1997), adenocarcinoma of
breast (Elstner et al, 1998; Mueller et al, 1998; Clay et al, 1999),
colorectal adenocarcinoma and carcinoma (Sarraf et al, 1998;
Brockman et al, 1998; Kitamura et al, 1999), gastric adenocarci-
noma (Takahashi et al, 1999; Sato et al, 2000), pancreatic carci-
noma (Motomura et al, 2000), adenocarcinoma and carcinoma of
prostate (Kubota et al, 1998; Butler et al, 2000), transitional
epithelial cancer of urinary bladder (Guan et al, 1999), chorio
carcinoma of placenta (Keelan et al, 1999), carcinoma of lung and
non-small cell lung cancer (Chang and Szabo, 2000; Tsubouchi
et al, 2000) and myeloid leukaemias (Asou et al, 1999; Hirase et
al, 1999; Sugimura et al, 1999). In vivo study on xenograft of
human tumours in immunodeficient mice followed by troglitazone
treatment also provided similar results (Elstner et al, 1998; Kubota
et al, 1998; Sarraf et al, 1998). Ligand-mediated PPARg activation
in those cancer cells induced cell cycle arrest (Tontonoz et al,
1997; Brockman et al, 1998; Sugimura et al, 1999; Motomura et
al, 2000), differentiation (Tontonoz et al, 1997; Kubota et al, 1998;
Mueller et al, 1998; Sarraf et al, 1998; Chang and Szabo, 2000),
and apoptosis (Elstner et al, 1998; Clay et al, 1999; Keelan et al,
1999; Sato et al, 2000) or nonapoptotic cell death (Kubota et al,
1998; Butler et al, 2000). Recently, troglitazone has been used in
clinical trial for the patients with advanced liposarcoma (Demetri
et al, 1999) and for patients with advanced prostate cancer
(Hisatake et al, 2000; Mueller et al, 2000). The drug was found to
induce histologic and biochemical differentiation in liposarcoma
and a prolonged stabilization of prostate-specific antigen (PSA)
level in prostate cancer patients. Such results suggest that ligands
of PPARg may serve as a biological modifier in human cancers and
the therapeutic potential should be further investigated. Human
liver tissue has been reported to express PPARg (Auboeuf et al,
1997; Vidal-Puig et al, 1997), however, expression of PPARg in
human hepatocellular carcinoma (HCC) and the effect of PPARg
agonists have not yet been studied and this study was designed to
investigate that. 
PPARg can be activated by certain polyunsaturated fatty acids
(Kliewer et al, 1997; Xu et al, 1999), prostaglandin J2 metabolite
15-deoxy-∆ 12,14-PGJ2 (15d-PGJ2) (Forman et al, 1995; Kliewer et
al, 1995), the thiazolidinedione (TZD) class of antidiabetic drugs
(Lehmann et al, 1995; Elbrecht et al, 1996) and a variety of nons-
teroidal anti-inflammatory drugs (Lehmann et al, 1997). Recent
attention has focused on troglitazone because of its rare but poten-
tially lethal hepatotoxicity (Watkins and Whitcomb, 1998;
Kohlroser et al, 2000) although at present, no similar side effects
have been observed with other TZD, either rosiglitazone or piogli-
tazone (Henney, 1999). Because evidence to date does not indicate
that hepatotoxicity is attributable to TZDs as a class or to PPARg
agonists in general, in vitro growth inhibitory effects of PPARg
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ligands were studied on human HCC cells in view of evaluating
their potential therapeutic application. 
MATERIALS AND METHODS 
Cell lines and culture condition 
Hepatocellular carcinoma cell lines Hep G2 was obtained from
American Type Culture Collection (Manassas, VA, USA), HuH-7
from JCRB Cell Bank (National Institute of Health Sciences,
Osaka, Japan) whereas, KYN-1 and KYN-2 were kind gifts from
Prof M Kojiro (Department of Pathology, Kurume University
School of Medicine, Japan). Hep G2 (Aden et al, 1979), as well as
HuH-7 (Nakabayashi et al, 1982) was established from well differ-
entiated hepatocellular carcinoma, KYN-1 (Yano et al, 1986) from
a moderately differentiated, and KYN-2 from a pleomorphic hepa-
tocellular carcinoma corresponding to Edmondson-Steiner grade
III (Yano et al, 1988). All the hepatocellular carcinoma cell lines
secrete albumin and AFP, in addition, KYN-1 possesses the nature
of transformation to adenocarcinoma with production of muci-
carmin-positive materials (Yano et al, 1986). Cells were grown at
37˚C in Dulbecco’s Modified Eagle Medium (DMEM) (Nissui
Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal
bovine serum (ICN Biomedicals, Aurora, Ohio, USA), L-gluta-
mine (ICN Biomedicals), penicillin-streptomycin (ICN
Biomedicals) and maintained in an incubator with 5% CO2 and
constant humidity. 
Sensitivity to PPARg ligands was studied in all the cell lines.
However, changes in cell cycle distribution caused by PPARg
ligands, as well as protein level of cyclin-dependent kinase (CDK)
inhibitors and a fetoprotein (AFP) or albumin mRNA expression
after troglitazone treatment were investigated using the representa-
tive cell line Hep G2. 
Experimental drugs 
Troglitazone (±)-5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-
2-ylmethoxy) benzyl]-2,4-thiazolidinedione, MW 441.55, was
kindly provided by Sankyo Pharmaceuticals Co (Tokyo, Japan)
and Pioglitazone (±)-5-[4-[2-(5-ethyl-2-pyridil) ethoxy]benzyl]-
thiazolidine-2,4-dione monohydrochloride (AD-4833 HCl),
MW 392.90, by Takeda Chemical Industries, Ltd (Tokyo, Japan).
15d-PGJ2, 15-deoxy-delta 12,14-prostaglandin J2, MW 316.4,
was purchased from Calbiochem (Calbiochem-Novabiochem
Corporation, La Jolla, CA, USA). All the experimental drugs were
prepared fresh before use, dissolving troglitazone or pioglitazone
in DMSO and 15d-PGJ2 in ethanol according to manufacturers
instruction. After dissolving the drugs in respective vehicles and
serially diluted, they were mixed into complete media to obtain the
desired concentration of the experimental drugs in solution and
then applied to the growing adherent cells. Vehicle concentration
in the medium was maintained 0.1% v/v for all. 
A dose ranging from 0.1 to 50 mM troglitazone was selected for
this in vitro study according to the pharmacokinetics (Plosker and
Faulds, 1999) and tissue distribution of the drug (Kawai et al,
1997). For comparison of the dose effect, the 2 other PPARg
ligands, pioglitazone and 15d-PGJ2 were also applied to cells at
the same dosages. 
Assays for PPARg expression 
RT-PCR 
PPARg expression at mRNA level was investigated by RT-PCR.
From each cell line, total RNA was extracted by Isogen (Nippon
Gene, Tokyo, Japan). 7.5 mg of total RNA was reverse transcribed
with oligo dT primer in a 50 ml reaction using ProstarTM First-
Strand RT-PCR kit (Stratagene Cloning Systems, La Jolla, CA,
USA). 1 ml of the cDNA was amplified by PCR on GeneAmp PCR
system 9600 (PE Applied Biosystems, Foster City, CA, USA).
Amplification was carried out in a 25 ml reaction volume using 
10 pmol of each of the primers (sense-5¢TCTGGCCCAC-
CAACTTTGGG 3¢ and antisense-5¢ CTTCACAAGCATGAACT-
CCA 3¢) (Kubota et al, 1998) with 200 mM each dNTP, 1.5 mM
MgCl2 and 0.75 unit of Amplitaq gold (PE Applied Biosystems)
for 30 cycles (94˚C 30 s, 56˚C 30 s and 72˚C 60 s). 5 ml of PCR
products were electrophoresced on 1.5% agarose gel with 0.5%
ethidium bromide and visualized on UV. As internal control, b-
actin cDNA sequence was amplified using the human b-actin
control amplimer set 5¢ ATCTGGCACCACACCTTCTACAAT-
GAGCTGCG 3¢ (sense) and 5¢ CGTCATACTCCTGCTTGCT-
GATCCACATCTGC 3¢ (antisense) (Clontech Laboratories, Palo
Alto, CA, USA). In all cases RNA processed without reverse tran-
scriptase and preparation without template was used to check
carryover and amplified products purified by Geneclean (Bio 101,
Carlstad, CA, USA) were confirmed by direct sequencing on ABI
prism 310 Genetic Analyser (PE Applied Biosystems) using
BigDye Terminator Cycle Sequencing kit (PE Applied Biosystems). 
Western blot 
Cells were lysed in 20 mM Tris, pH 7.6 containing 0.1% SDS, 1%
Triton-X 100, 1% deoxycholate and 100 mg ml–1 protease inhibitor
PMSF and proteins were extracted as described (Maekawa et al,
1997). Protein concentration was estimated in Bradford method
using BioRad Protein Assay Reagent (Bio-Rad, Hercules, CA,
USA). From each cell line, 50 mg of protein was separated by
12.5% SDS-PAGE (Multigel, Daiichi Pure Chemicals, Tokyo, Japan)
and transferred to polyvinylidene diflouride (PVDF) membrane
(Hybond-P, Amersham Pharmacia Biotech, Buckinghamshire, UK).
After 2 h blocking the membrane with 5% skim milk (Difco
Laboratories, Detroit, MI, USA) in TBS (20 mM Tris, 150 mM NaCl,
pH 7.6) and overnight incubation with mouse anti-human PPARg
monoclonal antibody (sc-7273, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) in 1:500 dilution at 4˚C, it was reacted with
peroxidase-conjugated anti-mouse IgG (1:2000) (Dako Cor-
poration, Carpinteria, CA, USA) washed in TTBS (TBS plus
0.05% Tween 20) followed by TBS and resulting signals were
imaged by enhanced chemiluminescence (ECL) detection system
(Amersham Pharmacia Biotech). 
PPARg functional assay 
To investigate whether PPARg expressed in HCC cell lines are
functionally active, we measured the reporter gene activity using
luciferase assay (Alam and Cook, 1990; Brasier et al, 1989;
Nordeen, 1988). Induction of the transcriptional activation by
PPARg ligand troglitazone through PPRE (Kliewer et al, 1992;
Juge-Aubry et al, 1997) was assessed by the luciferase assay after
transfecting Hep G2 cells a eukaryotic expression vector of firefly
luciferase with PPRE cloned upstream to its SV40 promoter.
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synthesized as described (He et al, 1999). Oligonucleotides 5¢
GATCCGGACCAGGACAAAGGTCACGTTCGGACCAGGA-
CAAAGGTCACGTTCGTCCTQQTCCQ3¢ and 5¢GATCCGAA-
CGTGACCTTTGTCCTGGTCCGAACGTGACCTTTGTCCTG
GTCCG 3¢ were annealed and 2 copies were cloned into the
multiple cloning site (MCS) upstream to SV40 promoter of the
PicaGene promoter vector (PGV-P2) (Nippon Gene) to construct
PGVP2.PPRE. Standard dual luciferase assay was performed in
24-well plates, transfecting 105 cells well–1 with 1 mg of
PGVP2.PPRE and 0.05 mg of PicaGene SeaPansy TK control
vector (pRL-TK) (Nippon Gene) using DOTAP liposomal trans-
fection reagent (Roche Molecular Biochemicals, Mannheim,
Germany). 10 h after the transfection, fresh media containing 10
mM troglitazone or vehicle only was added to the transfected cells.
After 12 h treatment with troglitazone, cells were lysed with
passive lysis buffer and luciferase assay was performed with
PicaGene Dual SeaPansy Luminescence Kit (Nippon Gene) on
Lumat LB9506 luminometer (EG & G Berthhold, Bad Wildbad,
Germany). Results were evaluated after normalization of the
firefly luciferase activity of PGVP2.PPRE with that of sea pansy
luciferase activity of pRL-TK. Tests were performed in duplicate,
repeated twice and the mean value of increment in luciferase
activity were analysed. 
Assessment of growth inhibition 
Viable cell counting 
Effect on cell growth was evaluated by direct cell counting using a
haemocytometer. 5 ´ 105 cells were seeded into 60 mm plates and
after 24 h, PPARg ligand troglitazone, pioglitazone or 15d-PGJ2
was added to culture media in 10, 25 and 50 mM concentration.
After 48 h, both floating and adherent cells were harvested and
viable cells were counted by trypan blue dye exclusion. Relative
rate of increment in cell counts in presence of ligands compared
with that of control without drug was considered representative of
cell growth. 
Assay for DNA synthesis 
DNA synthesis was assessed by 3H-thymidine incorporation. 105
cells were seeded into 24-well plates and after 24 h culture in
complete media, experimental drugs in varying concentrations
dissolved in media was added to the growing cells. After 24 h
treatment with drug, 1 mCi [methyl-3H]-thymidine (Amersham
Pharmacia Biotech) was added to each well and incubated for a
further 6 h. Then the cells were trypsinated and harvested onto a
glassfibre filtermat by a cell harvester, dried 1 h and 3H-thymidine
incorporation was measured with 1450 MicrobetaTM scintillation
counter (Wallac Oy, Turku, Finland). Assays were performed in
triplicate, the mean CPM values after normalization were analysed
for relative 3H-thymidine incorporation and repeated thrice. 
Cell cycle analysis 
Cell-cycle analysis was performed on the representative Hep G2
cells. Approximately 2 ´ 106 cells were seeded in 100 mm plates
and on growing cells, fresh media with experimental drugs in
various concentrations was added. Depending on the results of
viable cell counts and 3H-thymidine incorporation assay results,
troglitazone and pioglitazone was used in 10, 25 and 50 mM and
15d-PGJ2 in 5, 10 and 25 mM. After 48 h drug treatment, cells
were harvested, washed with PBS and fixed overnight in cold 
(– 20˚C) 75% ethanol. Ethanol fixed cells were washed twice with
ice cold PBS, and then approximately equal number of control or
drug treated cells were treated with 200 mg ml–1 RNase for 60 min
at 37˚C and stained with 100 mg ml–1 propidium iodide 30 min at
room temperature in dark. Cellular DNA contents were analysed
by flow cytometry (EPICS Elite, Coulter Electronics, FL, USA).
In each case, histogram of DNA contents in 10 000 cells were
analysed using Multicycle AV software (Phoenix, San Diego, CA,
USA) to evaluate relative distribution of cells in G1, S and G2
phase. Cell cycle analysis on Hep G2 cells was performed in dupli-
cate and repeated 3 times for each drug. 
Expression of cyclin-dependent kinase (CDK) inhibitors 
The effect of troglitazone on the expression of CDK inhibitor
p27Kipl, p21Cipl/Wafl and p18Ink4c was studied in Hep G2 cells by
Western blot analysis. Hep G2 cells were treated with 5, 10, 25 and
50 mM troglitazone or vehicle only and total proteins were
extracted 48 h after drug treatment. 50 mg of protein were sepa-
rated by 15–25% gradient SDS-PAGE (Multigel, Daiichi Pure
Chemicals) and transferred to PVDF membrane (Hybond-P,
Amersham Pharmacia Biotech). Then the membranes were
blocked with 5% skim milk in TBS at room temperature for 2 h,
and reacted overnight at 4˚C on a rotatory shaker with primary
mouse monoclonal antibody to human p27Kipl (1:500) (sc-1641,
Santa Cruz Biotechnology), or p21Cipl/Wafl (1:500) (OP64,
Oncogene Research Products, Calbiochem-Novabiochem, Inter-
national) or p18Ink4c (1:100) (sc-9965, Santa Cruz Biotechnology)
or b-actin (1:5000) (AC-15, Sigma Chemical Co, St Louis, MO,
USA). After washing the membranes in TTBSmilk, reacted with
HRP-conjugated anti-mouse IgG (1:1500 for anti-CDK inhibitors
or 1:3000 for anti-b-actin) (Dako Corporation) for 2 h at room
temperature, washed in TTBS followed by TBS and ECL detec-
tion reagent (Amersham Pharmacia Biotech) was used to visualize
the signals from immune complexes. 
Northern blot analysis for albumin and AFP expression 
Whether troglitazone induced differentiation in hepatocellular
carcinoma cells, was investigated after 2 ´ 48 h pulse exposure of
Hep G2 cells with troglitazone in varying concentrations.
Extracted total RNA was used in Northern blot analysis for the
quantitative comparison in the expression of albumin and AFP.
Briefly, 10 mg of total RNA was electrophoresced in formalde-
hyde-containing 1% agarose gel and transferred to nitrocellulose
membrane (Hybond-C Extra, Amersham Pharmacia Biotech),
followed by UV cross-linking (Funa-UV-linker, Funakoshi,
Tokyo, Japan). 32P-labelled (Multiprime DNA labelling systems,
Amersham Pharmacia Biotech) probes used for the Northern blot
analysis were a 422 bp cDNA fragment of human albumin (Niwa
et al, 1996), a 395 bp cDNA fragment of human AFP (Niwa et al,
1996) and the 838 bp cDNA fragment of human b-actin (RT-PCR,
internal control). After 4 h prehybridization, hybridization was
carried out for 20 h at 42˚C and then membranes were washed
twice at 37˚C in 2 ´ SSC containing 0.2% SDS for 10 min and
once at 50˚C in 0.1 ´ SSC containing 0.2% SDS for 30 min.
Autoradiography was performed using FUJIX BAS-2000 II (Fuji
Photo Film, Tokyo, Japan) and photographed with a FUJIX
Pictrography 3000 (Fuji Photo Film). The relative intensities of
message bands were quantified using the FUJIX-BAS 2000 II
Image Analyser. Statistical analysis 
Data were expressed as mean ± SE. Values were compared 
and significant differences between means were determined by
Analysis of Variance (ANOVA). Multiple comparisons were done
by Least Significant Difference (LSD) test after ANOVA. P values
< 0.05 were considered significant. 
RESULTS 
HCC cell lines expressed PPARg
RT-PCR analysis readily detected the expression of PPARg mRNA
in HCC cell line Hep G2, HuH-7, KYN-1 and KYN-2 (Figure 1A).
Amplified fragment was appropriate for 360 bp (Kubota et al,
1998) and direct sequencing also confirmed that RT-PCR products
were identical to human PPARg cDNA sequence (Elbrecht et al,
1996). Western blot analysis with anti-human PPARg monoclonal
antibody also detected expression of PPARg in all HCC cell lines
(Figure 1B) with molecular mass of approximately 54 kDa
(Elbrecht et al, 1996). 
Expressed PPARg was functional 
Transactivation experiment showed that 10 mM troglitazone
induced about 2.2 to 3.8 fold enhanced luciferase activity (Figure
1C) in all the HCC cell lines transfected with a luciferase reporter
vector containing PPRE upstream to SV40 promoter. Although
induction of luciferase activity was relatively lower in KYN-1 and
KYN-2, the differences were not significant. 
PPARg ligands induced growth inhibition 
Trypan blue staining and direct counting of viable cells 48 h after
troglitazone treatment at 10, 25 and 50 mM concentration showed
a significant decrease in relative increment cell number in all cell
lines (Figure 2A). With equivalent dose, 15d-PGJ2 also reduced
the viable cell count of Hep G2 significantly (Figure 2B).
However, at higher concentration (i.e. 25 and 50 mM) of 15d-PGJ2
and troglitazone, cell death was marked. Pioglitazone induced
inhibition of cell growth was quantitatively less than that 
of troglitazone and 15d-PGJ2 as observed on Hep G2 cells 
(Figure 2B). 
PPARg-induced growth inhibition of hepatocellular carcinoma 1643
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Figure 1 PPARg is expressed and functionally active in human
hepatocellular carcinoma cell lines. (A) PPARg expression at mRNA level.
Total RNA extracted from the cell lines was reverse transcribed and cDNA
was subjected to PCR for PPARg amplification. b-actin cDNA was also
amplified as internal control. (B) PPARg protein expression in hepatocellular
carcinoma cell lines detected by Western blot using monoclonal anti-
hPPARg. (C) PPRE transactivation in hepatocellular carcinoma cells: reporter
gene assay showed that a 12 h activation with 10 mM troglitazone induced a
significantly enhanced expression (2.2–3.8 fold induction) of luciferase in all
cell lines 
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Figure 2 Effect of PPARg ligands on proliferation of hepatocellular
carcinoma cell lines. Cells were incubated in presence or absence (control)
of PPARg ligands and after 48 h, total number of viable cells was counted by
trypan blue dye exclusion. Increment of cell number with drugs is expressed
compared with that of control. Each value indicates the mean ± SE of 3
experiments in duplicate. (A) Troglitazone dose dependently induced a
significant inhibition in increment of cell number in all 4-cell lines (P < 0.006).
(B) Effects of different PPARg ligands on HepG2 cells, showing that
pioglitazone and 15d-PGJ2 also significantly inhibited the cell number
increment (P = 0.000) PPARg ligands inhibited DNA synthesis 
Troglitazone induced inhibition of DNA synthesis as evidenced by
3H-thymidine incorporation in all the HCC cell lines after 30 h
drug treatment. There was a significant dose-dependent decrease
in 3H-thymidine incorporation with all concentrations of troglita-
zone used starting from 1 mM in Hep G2, HuH-7 and KYN-1 but 5
mM in KYN-2 (Figure 3A). More than 95% inhibition was
observed in all cell lines at 50 mM troglitazone, about 80% at 
25 mM and nearly 50% at 10 mM (Figure 3A). Pioglitazone
induced inhibition of 3H-thymidine incorporation was found
significant from 1 mM onward in Hep G2, KYN-1 and KYN-2 but
5 mM in HuH-7 (Figure 3B). However, 15d-PGJ2 mediated signif-
icant inhibition at 1 mM in KYN-2 cells and from 5 mM in other
cell lines (Figure 3C). 
PPARg ligands altered cell cycle progression 
The cell cycle distribution changes were evident after exposure of
Hep G2 cells to troglitazone, pioglitazone and 15d-PGJ2 (Figure
4). With increasing dose of the ligands, cell cycle distribution
significantly increased in G1 phase and decreased in S phase
(Figure 4). In addition, 15d-PGJ2 also induced a significant
increase in G2 phase (Figure 4C). Although G2 phase increased
slightly with troglitazone (Figure 4A), the dose-dependent G2
changes with troglitazone or pioglitazone were found to be 
statistically insignificant. 
Troglitazone increased p27Kipl and p18Ink4c protein levels 
Quantitative comparison of dose-dependent changes in the CDK
inhibitor levels in Hep G2 cells after troglitazone treatment is
shown in Figure 5 (A, B and C). Cell cycle arrest evident at 48 h
troglitazone treatment was associated with a dose-dependent
increase in CDK inhibitor p27Kipl and p18Ink4c, with a decline in
p21Cipl/Wafl level. 
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Figure 3 PPARg ligands induced inhibition of DNA synthesis in
hepatocellular carcinoma cell lines. Cells were treated with ligands in 0.1 to
50 mM concentration and after 24 h, a standard 3H-thymidine incorporation
assay was performed. Data represent mean ± SE values from 3 assays in
triplicate wells. (A) Troglitazone dose dependently induced inhibition of 3H-
thymidine incorporation in all of 4 HCC cell lines. * indicates significant
inhibition (P < 0.05) for Hep G2, HuH-7 and KYN-1, ** for all cell lines. 
(B) Pioglitazone-induced inhibition of 3H-thymidine incorporation, * indicates
significant inhibition (P < 0.05) for Hep G2, KYN-1 and KYN-2, ** for all cell
lines. (C) 15d-PGJ2 treatment also resulted in a similar inhibition in 3H-
thymidine incorporation. * indicates significant inhibition (P < 0.05) for KYN-2,
** for all cell lines 
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Figure 4 PPARg ligands induced inhibition of cell cycle progression.
Histogram of propidium iodide (PI) stained DNA contents of HepG2 cells,
showing a markedly increased G1 phase and decreased S phase after 48 h
treatment with 0, 10 and 50 mM troglitazone (A), 0, 10 and 50 mM
pioglitazone (B), 0, 10 and 25 mM 15d-PGJ2 (C). G2 increase was also
observed with troglitazone and 15d-PGJ2PPARg-induced growth inhibition of hepatocellular carcinoma 1645
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Troglitazone decreased AFP expression 
Northern blot analysis on RNA extracted from Hep G2 cells after
exposure to troglitazone, revealed that expression of AFP de-
creased while there was a little increase in the expression of
albumin in 5 and 10 mM but decreased at 25 mM (Figure 6A). On
repeated experiments, it was found that even with a decreased
albumin expression at 25 mM troglitazone, the ratio of albumin
versus AFP expression increased consistently in a dose-dependent
way (Figure 6B). 
DISCUSSION 
Drugs acting through PPARg have growth inhibitory effects on
certain human cancers. Both thiazolidinedione and nonthiazo-
lidinedione ligands have been shown to exert the inhibitory effect.
In this study, we evaluated the initial aspects of growth inhibitory
potential of PPARg agonists on human HCC cell lines using the
commonly studied TZD ligand troglitazone, a nonhepatotoxic
TZD pioglitazone and the endogenous ligand 15d-PGJ2. We found
that human HCC cell lines Hep G2, HuH-7, KYN-1 and KYN-2
express PPARg and the expressed PPARg was functionally active.
PPARg ligands also induced growth inhibition in all the HCC cell
lines. Compared to the rate of cell-count increment in drug-free
control, troglitazone as well as pioglitazone and 15d-PGJ2 caused
a significant inhibition in cell growth. Inhibition of cell prolifera-
tion was also evident in 3H-thymidine incorporation assays indi-
cating that PPARg ligands induced inhibition of DNA synthesis in
HCC cell lines. A similar dose response in inhibition of thymidine
incorporation was also reported on colon cancer cells (Kitamura et
al, 1999). 
Regarding the dose response of troglitazone in this study, a
significant growth inhibition could be obtained at 1 mM in 3 of the
4 cell lines, with marked inhibition in all at 5 mM. The other 2
PPARg ligands also exhibited similar dose responses. According to
the pharmacokinetics of troglitazone (Ploskar and Faulds, 1999)
and due to a higher tissue distribution in liver (Kawai et al, 1997),
a daily dose of 600 to 800 mg troglitazone may attain an effective
drug level in vivo. Similarly, 30 to 60 mg daily dose of pioglita-
zone would result in an effective drug level. In a recent clinical
trial on prostate cancer patients, 800 mg daily dose of troglitazone
has already been used (Mueller et al, 2000). 
Although the exact mechanism of growth inhibition of tumour
cells by PPARg ligands is not well-understood (Gelman et al,
1999), it was reported to be associated with alteration in the cell
cycle. Activation of PPARg resulted in G1 cell cycle arrest in
colon cancer cells (Brockman et al, 1998; Kitamura et al, 1999),
pancreatic cancer cells (Motomura et al, 2000) and leukaemia cells
(Asou et al, 1999; Sugimura et al, 1999). We found that all PPARg
ligands dose dependently increased Hep G2 cells accumulating in
G1 phase and decreased in S phase. Moreover, 15d-PGJ2 and to a
lesser extent troglitazone, induced also G2 cell cycle arrest. A G2
arrest in addition to G1 cell cycle arrest may be responsible for the
higher growth inhibitory potential of 15d-PGJ2 and troglitazone
over pioglitazone. 
To reveal the underlying mechanism of troglitazone-induced
cell cycle arrest, CDK inhibitor p27Kipl, p21Cipl/Wafl and p18Ink4c
protein levels were studied in Hep G2 cells. A dose-dependent
increase in p27Kipl and p18Ink4c with decreased p21Cipl/Wafl level was
observed 48 h after troglitazone treatment. The exact mechanism
of cell cycle withdrawal induced by PPARg ligands is not yet clear
but it was found related to up-regulation of p21Cipl/Wafl in eosinophilic
leukaemia cell line EoL-1 (Sugimura et al, 1999). In a recent study,
troglitazone induced G1 arrest in pancreatic carcinoma cell line 
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Figure 5 Effect of troglitazone on CDK inhibitor p27Kip1, p21Cip1/waf1 and
p18Ink4c protein level in Hep G2 cells. Troglitazone treatment dose
dependently increased the p27Kip1 (A) as well as p18Ink4c (B), with a
decreased p21Cip1/Waf1 level (C). 48 h after troglitazone treatment at 0, 5, 10,
25 and 50 mM concentration, proteins were extracted and Western blots were
performed with mouse monoclonal antibody to human p27Kip1, p21Cip1/Waf1 and
p18Ink4c. As internal control, b-actin (42 kDa) was detected using a mouse
monoclonal antibody. Below each lane, dosages of troglitazone are indicated 
90
80
70
60
50
40
30
20
10
0
0 5.0 10.0 25.0
Troglitazone (mM)
A
l
b
u
m
i
n
/
f
e
t
o
p
r
o
t
e
i
n
 
r
a
t
i
o
(
%
 
i
n
c
r
e
a
s
e
)
*
*
*
A
B
a fetoprotein Albumin
0 5 10 25
b
-
a
c
t
i
n
Troglitazone (mM)
0 5 10 25
Troglitazone (mM)
Figure 6 Troglitazone effects on AFP and albumin expression in Hep G2
cells. (A) Autoradiogram of a representative Northern blot showing effects of
troglitazone on AFP and albumin expression. Detection of b-actin expression
was used as internal control. (B) Northern analysis data representing ratio of
albumin and AFP message signals. Values are expressed compared to that
of the control. Mean ± SE values from 4 different experiments show that
troglitazone dose dependently increase the ratio of albumin/AFP expression.
* indicates significant (P < 0.05) increase PK-1 was found to be associated with increased p27Kipl but
unchanged p21Cipl/Wafl and p18Ink4c levels (Motomura et al, 2000).
Cell cycle withdrawal during PPARg induced adipogenesis was
also found associated with an initial increase in both p27Kipl and
p21Cipl/Wafl, followed by a decline in p21Cipl/Wafl, increase in p18Ink4c
with sustained p27Kipl level (Morrison and Farmer, 1999).
Difference in the extent of G1 or G2 cell cycle arrest in Hep G2
cells with troglitazone, pioglitazone or 15d-PGJ2 may be due to
differences in cascade expression of the CDK inhibitors. However,
CDK inhibitors other than p27Kipl, p21Cipl/Wafl and p18Ink4c may also
be involved in the PPARg ligands induced cell cycle arrest.
Possibility of an initial increased p21Cipl/Wafl followed by declined
level in troglitazone treated Hep G2 cells as reported in coupling
growth arrest and adipocyte differentiation (Morrison and Farmer,
1999) can not be excluded until further time course studies are
done. Further studies are also required to reveal whether inhibition
of the p27Kipl or p18Ink4c increase could inhibit the growth arrest in
Hep G2 as found in PK-1 cells (Motomura et al, 2000). 
PPARg ligands have been shown to drive differentiation process
in various malignant cells (Tontonoz et al, 1997; Kubota et al,
1998; Sarraf et al, 1998; Chang and Szabo, 2000). When we inves-
tigated the expression of AFP and albumin in Hep G2 cells after
treatment with troglitazone, we found that there was a dose-
dependent decrease in the AFP expression. The expression of
albumin showed a little increase with 5 and 10 mM troglitazone
but decrease with 25 mM. The decreased albumin expression at 25
mM may be due to associated cytotoxic response of troglitazone on
Hep G2 cells. However, the inhibition of AFP expression was
more prominent over albumin inhibition and results of repeated
Northern analysis revealed that instead of variation in the amount
of decrease in AFP expression or increase in albumin expression,
the dose-dependent increase in ratio of albumin and AFP expres-
sion remained consistent. 
Hepatocellular carcinoma is one of the most lethal malignancies
where chemoprevention is recommended and different type newer
agents are already tried on human subjects (Oka et al, 1995; Muto
et al, 1996; Jacobson et al, 1997). PPARg ligands exhibited a
marked growth inhibitory potential on hepatocellular carcinoma
cells through induction of G1 cell cycle arrest and recent studies
have also shown that activation of PPARg can inhibit the profibro-
genic and proinflammatory actions of hepatic stellate cells (Galli
et al, 2000; Marra et al, 2000; Miyahara et al, 2000). Taken
together, we conclude that PPARg ligands may also prove benefi-
cial for primary or secondary chemoprevention of hepatocellular
carcinoma. However, further studies will be necessary to evaluate
their safety and therapeutic potential. 
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